跳至主要内容
临床试验/ITMCTR2000003330
ITMCTR2000003330尚未招募1 期

Study for the innovative clinical protocol and application of treating gastric cancer by the rule of ''the body and spirit, stasis, toxin and depression together''

Affiliated Cancer Hospital of Zhejiang Chinese Medical University0 个研究点开始时间: 待定最近更新:
适应症

试验速览

阶段
1 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

年龄范围
18 至 75(—)
性别
All

入选标准

  • 1. The patients with TNM stage III gastric cancer were diagnosed by pathology, and D2 radical operation had been performed, and chemotherapy had not been started;
  • 2. The syndrome differentiation of traditional Chinese medicine is the syndrome of stasis, toxin and depression;
  • 3. Patients aged 18 to 75 years;
  • 4. Patients with good general condition and ECoG score <=2;
  • 5. The subjects must have informed consent before the test, fully understand the test content, process and possible adverse reactions, and sign the written informed consent voluntarily.

排除标准

  • 1. Patients with gastric cancer metastasis or recurrence, or with other tumors within 5 years;
  • 2. Patients with expected survival time <=3 months;
  • 3. Patients with severe malnutrition, primary diseases of heart, brain, lung, liver, kidney, endocrine, blood, nervous system or other acute and chronic diseases that may significantly affect the treatment and prognosis;
  • 4. Patients with history or risk of epilepsy;
  • 5. Patients with dementia or severe mental disorder who cannot understand or express informed consent;
  • 6. Current or previous patients with a history of alcohol or drug abuse or drug abuse;
  • 7. Male subjects (or their partners) or female subjects have birth plans or egg donation plans within 28 days before screening and 6 months after the last administration of the study drug, and are unwilling to take one or more non drug contraceptive measures (such as complete abstinence, contraceptive ring, partner ligation, etc.) during the trial period;
  • 8. Pregnant, pregnant or lactating patients;
  • 9. Patients who are participating in other clinical studies;
  • 10. Patients who are allergic to the test drug and its components;
  • 11. Patients who can not swallow tablets or traditional Chinese medicine decoction, malabsorption syndrome or any condition affecting gastrointestinal absorption;
  • 12. Patients with active tuberculosis (TB) are receiving anti TB treatment or have received anti TB treatment within one year before screening;
  • 13. Patients who were not considered suitable for the study.

研究者

发起方
Affiliated Cancer Hospital of Zhejiang Chinese Medical University

相似试验